Yu-Bai Chou
Overview
Explore the profile of Yu-Bai Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Yang C, Weng C, Chou Y, Huang Y, Hwang D, Chen S, et al.
J Stroke Cerebrovasc Dis
. 2025 Jan;
34(3):108240.
PMID: 39809373
Backgrounds/aims: Central retinal artery occlusion (CRAO) is a vision-devastating emergency. However, widely-acknowledged treatment consensus is lacking and prehospital delays commonly occur. Hence, we aimed to investigate the visual outcomes of...
3.
4.
Chou Y, Chang J, Chou Y, Pu C
Sci Rep
. 2024 Oct;
14(1):26098.
PMID: 39478134
To determine the correlation between the severity of chronic kidney disease (CKD) and treatment of diabetic macular edema (DME). The retrospective 2-year cohort study included eyes with DME confirmed using...
5.
Chang H, Chi S, Chen S, Chou Y, Lin T
Ophthalmol Ther
. 2024 Oct;
13(12):3149-3159.
PMID: 39453591
Introduction: This study aimed to investigate the impact of aflibercept and dexamethasone (DEX) on the formation of epiretinal membrane (ERM) and their treatment outcomes in eyes with diabetic macular edema...
6.
Chi S, Weng C, Chen S, Lin T, Chou Y, Hwang D
Ophthalmologica
. 2024 Aug;
247(5-6):312-321.
PMID: 39197428
Introduction: Anti-vascular endothelial growth factor (VEGF) treatment stands as the primary approach for neovascular age-related macular degeneration (nAMD). Faricimab has recently emerged as a novel anti-VEGF option for nAMD. This...
7.
Chou Y, Chang H, Chiu H, Chou Y, Pu C
Ophthalmic Epidemiol
. 2024 Jul;
32(2):204-212.
PMID: 39083572
Purpose: To explore potential risk factors for the development of neovascular glaucoma (NVG) in central retinal vein occlusion (CRVO) over a two-year intensive follow-up period. Methods: This study reviewed 1545...
8.
Cheng C, Chou Y, Tsai C, Hsieh M, Hsiao C, Lai T
Taiwan J Ophthalmol
. 2024 Apr;
14(1):95-101.
PMID: 38654989
Purpose: The purpose of the study was to report the complications of sutureless intrascleral (SIS) intraocular lens (IOL) fixation and its management. Materials And Methods: A multicenter, retrospective, consecutive interventional...
9.
Tseng Y, Hsu C, Chou Y
Eye (Lond)
. 2024 Apr;
38(10):1882-1890.
PMID: 38565600
Background: Uveal melanoma (UM) is the most common primary ocular tumour in adults. The most used eye-preserving treatments are charged-particle therapy (CPT) and brachytherapy. We performed a systematic review and...
10.
Weng C, Chi S, Lin T, Huang Y, Chou Y, Hwang D, et al.
PLoS One
. 2024 Apr;
19(4):e0301096.
PMID: 38564612
This retrospective study aimed to determine the short-term efficacy and safety of brolucizumab treatment for recalcitrant neovascular age-related macular degeneration (nAMD) in a real-world setting in Taiwan. Recalcitrant nAMD patients...